TLSI

TriSalus Life Sciences Inc

Add to Watchlist

Advanced Chart

4.500

-0.07(-1.532%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.5993

Open

4.410

VWAP

4.52

Vol

62.89K

Mkt Cap

170.28M

Low

4.410

Amount

284.12K

EV/EBITDA(TTM)

Total Shares

27.16M

192.76M

EV/OCF(TTM)

P/S(TTM)

3.81

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. The Company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

13.32M

+61.27%

11.65M

+58.54%

10.69M

+45.2%

Estimates Revision

The market is revising Upward the revenue expectations for TriSalus Life Sciences, Inc. (TLSI) for FY2025, with the revenue forecasts being adjusted by 0.17% over the past three months. During the same period, the stock price has changed by -21.33%.

Revenue Estimates for FY2025

Revise Upward

+0.17%

In Past 3 Month

Stock Price

Go Down

-21.33%

In Past 3 Month

7 Analyst Rating

155.56% Upside

Wall Street analysts forecast TLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLSI is 11.50 USD with a low forecast of 9.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

155.56% Upside

Current: 4.500

Low

9.00

Averages

11.50

High

16.00

155.56% Upside

Current: 4.500

Low

9.00

Averages

11.50

High

16.00

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$11

2025-03-28

Reason

Canaccord Genuity

William Plovanic

Price Target

$11

2025-03-28

Maintains

Strong Buy

Reason

Roth MKM

Jason Wittes

Strong Buy

Reiterates

$11

2025-01-24

Reason

Roth MKM

Jason Wittes

Price Target

$11

2025-01-24

Reiterates

Strong Buy

Reason

Cantor Fitzgerald

Prakhar Agrawal

Buy

Initiates

$10

2024-12-17

Reason

Cantor Fitzgerald

Prakhar Agrawal

Price Target

$10

2024-12-17

Initiates

Buy

Reason

Cantor Fitzgerald initiated coverage of TriSalus Life Sciences with an Overweight rating and $10 price target.

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$12 → $11

2024-11-15

Reason

Canaccord Genuity

William Plovanic

Price Target

$12 → $11

2024-11-15

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on TriSalus Life Sciences to $11 from $12 and keeps a Buy rating on the shares. The firm believes TriSalus has the foundation of a strong medical device business with a commercial footprint and catalysts to support it including new product launches and clinical data.

Roth MKM

Jason Wittes

Strong Buy

Initiates

$11

2024-11-11

Reason

Roth MKM

Jason Wittes

Price Target

$11

2024-11-11

Initiates

Strong Buy

Reason

Roth MKM analyst Jason Wittes initiated coverage of TriSalus Life Sciences with a Buy rating and $11 price target. The company's TriNav catheter significantly improves drug delivery with pressure enabled drug delivery, which is on its way to becoming the standard of care for delivering therapeutics to tumors in the liver, the analyst tells investors in a research note. The firm says this alone supports 50% growth through 2027, with upside from clinical expansion beyond the liver.

Northland Capital Markets

Carl Byrnes

Buy

Initiates

$13

2024-10-25

Reason

Northland Capital Markets

Carl Byrnes

Price Target

$13

2024-10-25

Initiates

Buy

Reason

Northland analyst Carl Byrnes initiated coverage of TriSalus Life Sciences with an Outperform rating and $12.50 price target.

See All Ratings

Valuation Metrics

The current forward P/E ratio for TriSalus Life Sciences Inc (TLSI.O) is -8.37, compared to its 5-year average forward P/E of -2.95. For a more detailed relative valuation and DCF analysis to assess TriSalus Life Sciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.95

Current PE

-8.37

Overvalued PE

0.18

Undervalued PE

-6.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.35

Current EV/EBITDA

-19.64

Overvalued EV/EBITDA

3.08

Undervalued EV/EBITDA

-11.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.08

Current PS

3.36

Overvalued PS

6.54

Undervalued PS

-0.37

Financials

Annual

Quarterly

FY2025Q1

YoY :

+41.97%

9.17M

Total Revenue

FY2025Q1

YoY :

-37.28%

-7.33M

Operating Profit

FY2025Q1

YoY :

-21.51%

-10.38M

Net Income after Tax

FY2025Q1

YoY :

-35.00%

-0.39

EPS - Diluted

FY2025Q1

YoY :

-51.95%

-5.25M

Free Cash Flow

FY2025Q1

YoY :

-1.49%

83.69

Gross Profit Margin - %

FY2025Q1

YoY :

-52.43%

-110.48

FCF Margin - %

FY2025Q1

YoY :

-44.71%

-113.18

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

128.6K

USD

3-6

Months

0.0

USD

6-9

Months

110.7K

USD

0-12

Months

1.4K

USD

Bought

0-3

0.0

USD

Months

3-6

33.9K

USD

Months

6-9

708.7K

USD

Months

0-12

100.2K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

128.6K

USD

3-6

Months

0.0

USD

6-9

Months

110.7K

USD

0-12

Months

1.4K

USD

Bought

0-3

0.0

USD

Months

3-6

33.9K

USD

Months

6-9

708.7K

USD

Months

0-12

100.2K

USD

Months

TLSI News & Events

Events Timeline

2025-05-30 (ET)

2025-05-30

07:04:27

TriSalus Life Sciences appoints Patience as Chief Financial Officer

2025-05-15 (ET)

2025-05-15

07:07:50

TriSalus Life Sciences backs FY25 revenue view up 50%

2025-05-15

07:07:12

TriSalus Life Sciences reports Q1 EPS (39c), consensus (20c)

News

8.5

06-23Newsfilter

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

5.0

06-04NASDAQ.COM

TriSalus Launches TriNav FLX To Enhance Drug Delivery In Complex Peripheral Vessels

5.0

05-30Newsfilter

TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience